id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
DEA-2022-0025-0006,DEA,DEA-2022-0025,Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV,Rule,,2022-09-30T04:00:00Z,2022,9,2022-09-30T04:00:00Z,,2022-09-30T12:20:37Z,2022-21253,0,0,0900006485389e23
DEA-2022-0025-0003,DEA,DEA-2022-0025,Daridorexant eight factor document DOE,Supporting & Related Material,,2022-04-07T04:00:00Z,2022,4,,,2022-04-07T13:15:47Z,,0,0,0900006484fff9ea
DEA-2022-0025-0002,DEA,DEA-2022-0025,Daridorexant ASHtoDEA 22Dec2021,Supporting & Related Material,,2022-04-07T04:00:00Z,2022,4,,,2022-04-07T13:15:39Z,,0,0,0900006484fff9e9
DEA-2022-0025-0004,DEA,DEA-2022-0025,DCT to DEA daridorexant NDA approval notification,Supporting & Related Material,,2022-04-07T04:00:00Z,2022,4,,,2022-04-07T13:15:53Z,,0,0,0900006484fff7f5
DEA-2022-0025-0001,DEA,DEA-2022-0025,Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV,Rule,,2022-04-07T04:00:00Z,2022,4,2022-04-07T04:00:00Z,2022-05-10T03:59:59Z,2022-05-03T13:22:43Z,2022-07322,0,0,0900006484fff3ba